GlassScriptPhysician profile
Jillian L Stauffer
NPI 1699075580
$8,972.86
in general payments reported to CMS, 2019-2025
35 companies · $2,659 in 2025
The $2,659 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,363 · 2022: $1,347 · 2023: $1,906 · 2024: $1,697 · 2025: $2,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,088 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,088.03 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,491.60 | 2021-2025 | |
| Janssen Biotech, INC. | $965.98 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $866.14 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $531.66 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $488.42 | 2021-2025 | |
| Gilead Sciences, INC. | $424.36 | 2021-2025 | |
| Genzyme Corporation | $410.07 | 2022-2025 | |
| Celgene Corporation | $394.00 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $302.75 | 2021-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $188.51 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $188.12 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $187.56 | 2021-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $169.33 | 2021-2023 | Zinplava, Dificid |
| Ardelyx, INC. | $163.43 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $144.37 | 2025 | Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $139.67 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $129.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $96.18 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $85.78 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $85.13 | 2021-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $77.03 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $73.37 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $55.48 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $51.40 | 2021-2024 | |
| Fresenius Kabi USA, LLC | $40.82 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.15 | 2023-2024 | Cyltezo |
| Digestive Care, INC. | $29.14 | 2024 | Pertzye |
| Ipsen Biopharmaceuticals, INC | $26.35 | 2025 | Iqirvo |
| Novartis Pharmaceuticals Corporation | $26.22 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $24.30 | 2025 | Wainua |
| Amgen INC. | $17.96 | 2023 | Amjevita, Avsola |
| Sandoz INC. | $17.39 | 2023 | Hyrimoz |
| Alfasigma USA, INC. | $14.77 | 2022 | |
| Evoke Pharma, INC. | $14.70 | 2024 | |
| Alnylam Pharmaceuticals INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Stauffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.